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Background: A significant concern for patients treated for cancer is fear of cancer
recurrence (FCR). Although a common experience, some patients report high levels of
FCR that are difficult to manage and result in over vigilant checking and high use of
health services. There has been speculation about the relationship of FCR with gender
with mixed reports from several systematic reviews.
Aims: To determine the association of FCR with gender in previous reported studies
and investigate the strength of this relationship with various moderators including
year of publication, type of cancer and measurement attributes of self-reported
FCR instruments.
Methods: A systematic review was conducted with searches of the literature from the
MEDLINE, PubMed, Embase, and PsycINFO databases following PRISMA guidelines.
All the included papers were divided into two groups, namely: “pure” that comprise
only of patients with cancer types that both men and women can contract and “mixed”
that report on patients with a variety of cancer types. The association between gender
and FCR level was assessed by meta-analysis. A meta-regression was performed to
investigate the moderating effects of factors including: the year of publication, cancer
type, mean age of the sample and the length of the FCR scale measurement. This review
was registered with PROSPERO, ID: CRD42020184812.
Results: Finally, 29 studies were included. TheN size of pooled participants was 33,339.
The meta-analysis showed females to have an overall higher level of FCR than males (ES
= 0.30; 95% CI, 0.23, 0.36). The meta-regression of moderating or control variables
found little, if any, systematic variation in effect-sizes.
Conclusion: This systematic review has clarified a potentially confused pattern of
previous results in understanding the relationship between gender and FCR. Women
report higher levels of FCR thanmen and this feature is one that clinicians and researchers
can factor into their practice and future studies. The effect size is moderate, hence there
is ample variation in FCR level, independent of gender, that requires further investigation.
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INTRODUCTION
Fear of cancer recurrence (FCR), or fear of progression (FoP)
has been shown to be prevalent among cancer survivors, ranging
from a normal reaction to a clinically significant level (Yang et al.,
2017; Borreani et al., 2020). Through a rigorous consensus-based
procedure in 2016, the latest commonly accepted definition of
FCR is “fear, worry, or concern relating to the possibility that
cancer will come back or progress” (Lebel et al., 2016). It is
commonly reported to be the most significant concern of cancer
survivors and the most frequent issue they want to discuss in
consultations (Spencer et al., 1999; Lebel et al., 2007; Rogers
et al., 2009; Ashing-Giwa and Lim, 2011). It has also been one
of the most intensively studied areas of cancer-related health
worries and unmet needs (Deimling et al., 2006b; Tsay et al.,
2020). High-level FCR can lead to excessive checking behaviors
and psychological distress, estimated to feature in 10% of cancer
patients, as well as significant effects on associated mental health
constructs such as depression and quality of life (QoL) (Hodges
and Humphris, 2009; Tsay et al., 2020).
Researchers have been investigating factors associated with
high FCR level. Demographic characteristics, such as gender,
younger age, poorer education and lower income, may predict
higher FCR level. Several studies have reported that females
experience higher FCR than men (Wagner et al., 2018; Götze
et al., 2019; Leclair et al., 2019), while others have not found
any significant association between gender and FCR (Mullens
et al., 2004; Steele et al., 2007; Jeon et al., 2019), and very
few studies reported higher FCR in males (Yang et al., 2019;
Luo et al., 2020). To date there has been no review exclusively
focusing on the gender difference of FCR. Some comprehensive
systematic reviews investigated factors that influence FCR level,
including gender (Crist and Grunfeld, 2013; Koch et al., 2013;
Simard et al., 2013). The results of these studies were somewhat
contradictory. That is, they noted either that no results were
provided to show a gender difference comparison or that there
appeared to be little consensus, even when gender differences
were explored. For instance, in Simard’s review, only 4 studies
reported significant association between genders and FCR while
12 other studies reported “no significance.” Hence the number
of studies to examine a possible gender difference was relatively
small, and none of these reviews were able to draw a definite
conclusion about the role of gender.
Some cancers are gender-specific, such as ovarian, cervical,
uterus and prostate cancers, which only females or males could
contract. Breast cancer can be diagnosed in very few cases of men,
however, in terms of its rareness it is usually regarded as a gender-
specific cancer type as well. When assessing the factor of gender,
many studies included both gender-specific cancer types and
general cancer types, which both male and female can contract.
This may produce biased gender-related results because gender-
specific cancers only include patients of one gender, which may
result in a mix of gender and cancer type factors and a biased
gender distribution in a study sample. For example, more than
half of the sample of Stephens’ study (Stephens et al., 2016) are
breast/uterus and prostate cancers. The former are all women,
and the latter are all men. So, in this part of the sample (3,461 out
of 6,099), different genders had different cancer types. It is hard to
identify the exact effect level that either gender or cancer type is
responsible for. This might explain for example why Simard and
Savard’s study found that women reported higher FCR, which
included gender-specific cancer types such as breast and prostate
cancers, but the association disappeared when cancer types
were controlled (Simard and Savard, 2009). Moreover, gender-
specific cancers may result in additional mental health related
problems because these cancers are usually associated to the
genital system, sexual characteristics, and hormonal differences
(i.e., biological factors). It has been reported that some breast
cancer patients may undergo significant mental health problems
due to the negative psychological impact of the disease itself and
the experience of the treatment process (Capuron et al., 2000;
Ganz, 2001). Therefore, when analyzing the factor of gender, it
is necessary to control cancer types and especially distinguish
between gender-specific cancers and general cancers.
The reason to explore this potential gender difference with
greater attention is that the clinician can use the gender
classification as a potential reliable indicator of FCR. A similar
remark has already been raised by Lim and Humphris in their
review of FCR and patient age (Lim andHumphris, 2020). Hence,
the clinician who is aware of the patient’s gender (in addition to
knowledge of the patient’s age) may have the potential to predict
somewhat the FCR in patients attending out-patient clinics. The
present study therefore aims to conduct a systematic review
of quantitative studies to investigate the association between
gender and FCR level. Studies including gender-specific cancers
and those only including cancer that can be contracted by both
genders are analyzed, respectively, and compared. Furthermore,
to understand the reported systematic variation of discrepancies
between men and women in FCR level, we examined the possible
effects of publication year, cancer type, FCR measure and mean
age of the study sample.
METHODS
Protocol




The relevant studies (published between 01 April 2000 and 01
May 2020) were identified by searching MEDLINE, PubMed,
Embase, and PsycINFO databases, adhering to The Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) systematic review and meta-analysis guidelines
(Shamseer et al., 2015). We also included any study known
to the research team that had been submitted or in press in
peer-review journals.
The key search terms were (“fear” [MESH] OR worry OR
concern OR anxiety) AND (“neoplasm” [MESH] or cancer
or carcinoma) AND (“recurrence” [MESH] OR “neoplasm
recurrence” [MESH] OR progression OR return OR relapse OR
remit) AND (gender OR male OR female OR men OR women).
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Inclusion/Exclusion Criteria
Papers selected for inclusion had to (a) be published in
peer-reviewed journals between 01 April 2000 and 01 May
2020; (b) be written in English; (c) be quantitative studies
and (d) report the association between patient gender and
FCR or fear of progression (FoP) level in their results.
Qualitative studies, dissertations, editorials, conference abstracts
and commentaries were excluded. In addition, studies that
reported fear of recurrence of nonneoplastic or noncancerous
diseases were excluded.
Data Extraction
After removing duplicate studies, the titles and abstracts of
potential references were reviewed, and unsuitable ones were
excluded. Then full texts were acquired and examined. The
papers that completely fulfilled the inclusion criteria were
conserved and recorded. Data extraction was conducted by CP
and overviewed by GH. The following data were extracted for
each study: (a) Authors’ names, (b) year of publication, (c)
sample size of the study, (d) mean age of the sample, (e) cancer
types, (f) statistical data on gender and FCR/FoP association, (g)
difference direction (males or females that have higher FCR/FoP),
(h) FCR/FoP measure utilized (i) country of study, and (j)
study design.
For papers incorporated more than one wave of valid data
collection from different samples, each data collection was,
respectively, extracted as independent studies in our review
protocol. Where studies incorporated longitudinal waves of data
collections from the same sample, we decided a priori to extract
the association statistic from the baseline wave. The logic of
selecting the first instance of patient assessment in a panel study
was that it would likely have the largest sample size and hence
favorable statistical power.
Based on the cancer types included in each of the study
samples, all the included papers were divided into two groups.
Group 1 (pure group) included studies that exclusively have
cancers of one site or one system without gender-specific types.
Hence the patients in this group will have contracted cancer
such as head and neck cancer that affects both men and women.
Whereas, group 2 (mixed group) included the studies with a
number of cancer types including, or not including, gender-
specific cancers, such as studies with mixed ovarian, prostate and
other cancers. Although breast cancer can be contracted by men
in rare cases, it is also regarded as a gender-specific type because
the vast majority of the patients are women. Only one study in the
mixed group does not have gender-specific cancers (Langeveld
et al., 2004). Thus, in the pure group, we will be able to exclude the
potential bias caused by gender-specific cancers or other various
cancer types, while the studies with mixed cancer types were also
analyzed so that it could be compared with the pure group to
see if significant differences do exist. The cancer type will also be
analyzed globally as amoderator in the followingmeta-regression
to further investigate its possible effect on our results.
Quality Assessment
The Joanna Briggs Institute (JBI) critical appraisal checklist for
analytical cross-sectional studies was modified and applied to
the cross-sectional, longitudinal, and RCT studies included in
the present review (Aromataris et al., 2015; Lim and Humphris,
2020). The JBI checklist was an 8-item quality assessment tool.
We excluded two items for our review which were not applicable:
“was the exposure measured in a valid and reliable way” and
“were objective, standard criteria used for measurement of the
condition.” The assessment selections of “unclear” and “not
applicable” were merged into one. The 6-item tool was manually
applied to all 29 studies included in this review. The modified
checklist is presented in the Supplementary Material.
Statistical Analysis
Meta-Analysis
The meta-analysis of the two groups was conducted according to
PRISMA guidelines to assess the association between gender and
FCR in the included studies. The effect sizes were calculated using
Comprehensive Meta-analysis routines (version 2.0). The raw
correlation, odds ratio, t-test statistics or regression coefficients
were obtained from the original published papers for conversion
to an effect size in the analysis.
Heterogeneity
The heterogeneity estimates the variance among included studies,
demonstrating the difference between the true effect size and
the observed effect size. Measures of heterogeneity include Q
value (random error), T2 (variance of effect sizes), T (standard
deviation of effect sizes), and I2 (percentage heterogeneity)
(Borenstein et al., 2009). We adopted a random effects model as
the results tend to be more conservative and is considered more
meaningful. That is, it calculates an effect size that can be referred
to as a population estimate, as opposed to a fixed effects model
that is more limited in its reference to the studies included in
the review. In other words the random-effects model focuses not
only on the differences in the effect-size in each study but also the
sampling variability (chance).
Publication Bias
A conventional approach to publication bias was performed by
plotting a “funnel plot” of the selected studies. Studies that reside
outside pre-specified barriers or constraints can be identified. The
number and patterns of these publications in occupying outside
recognized contours would alert the review researcher to results
that may be biased. The formal statistical tests, namely: Eggers
and Beggs for reporting small study bias were performed. We
also ran a procedure known as “one study removed” to assist
with the detection of a single study that may distort the overall
effect size estimation. The meta-analysis was rerun repeatedly
and dropping in turn each study and replacing the previous
omission. The purpose of this commonly utilized approach was
to identify any major study that would influence unduly the final
set of included studies.
Meta-Regression
Meta-regression was used to evaluate the association between one
or more independent variables and effect size. It can be compared
with multiple regression because similar statistical methods are
used and it is possible to assess the relationship between the
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FIGURE 1 | Preferred reporting items for systematic reviews and meta-analyses (PRISMA) diagram.
determined quality (or the moderator variable) and the effect size
of each study (Thompson and Sharp, 1999; Higgins, 2011).
The analysis was performed adopting as the dependent
variable the effect size for each study as displayed in the forest
plot. With 29 studies therefore we have 29 effect sizes. We
then include as independent variables the 4 moderator variables
including the year of publication, cancer type, mean age of the
sample and the length of the FCR scale measurement (single-item
or multi-item).
The statistical results were produced by STATA15 software.
The measures of heterogeneity were also generated, such as T2,




The search process is shown in Figure 1. In total, 3,216 references
were identified from the four databases (EMBASE, MEDLINE,
PubMed, and PsycINFO). After the duplicates were excluded,
the remaining 2,971 titles and abstracts were scrutinized for
relevance. Preliminary screening identified 45 papers to be
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relevant. The full texts were obtained, and the data regarding
gender and FCR level were extracted. Finally, 26 papers were
included. As described in the Data Extraction section, two
included papers each incorporated twowaves of data collection of
different samples (Humphris et al., 2003; Deimling et al., 2006a).
These four waves of data were extracted as four independent
studies in the present review for analysis, entitled as Humphrisa,b
and Deimlinga,b in Table 1. Additionally, one set of data was
extracted from the Head & Neck 5000 study database, entitled
as (Head Neck 5000 - NHS Foundation Trust, 2016d) and is
being submitted. Hence the total number of studies for analysis
is 29, out of which 15 were included in pure group and 14 were
included in mixed group (Tables 1A,B).
Quality Assessment
Studies were all satisfactory as they were rated positively in half
or more of the six criteria (Tables 2A,B).
Overall Effect
The N size of pooled participants was 33,339, 16,493 in the
pure group and 16,846 in the mixed group. Two thirds of the
included studies (66% i.e., 19 out of 29) reported that females
have significantly higher FCR level. Two studies reported a
higher average mean FCR score for males. These were conducted
with separate samples from the Guangzhou Hospital Region
(Yang et al., 2019; Luo et al., 2020). The forest plot (Figure 2)
shows the effect sizes of the pure group and mixed group are,
respectively, 0.28 (95% confidence interval: 0.24–0.32) and 0.29
(95% confidence interval: 0.18–0.40), with an overall effect size
of 0.30 (95% CI: 0.23–0.36). The tests for the overall, pure, and
mixed group effect size are, respectively, z = 9.16 (p < 0.001), z
= 13.90 (p < 0.001), z = 5.34 (P < 0.001). With the “one study
removed” analysis it was found that the minimum overall effect
size reported was 0.284 demonstrating the very limited effect of
any single study to influence the overall results. A classic Fail-safe
N calculation resulted in 2,750+ studies would need to be found
to bring the effect size to a not significant value (p > 0.05).
Heterogeneity
The overall Q value for heterogeneity is 127.75 (df = 27, p <
0.001), I2 is 78%, and Tau2 is 0.034. The Q values of the pure
group and mixed group are 14.65 (df= 14, p= 0.403) and 105.40
(df= 13, p< 0.001), respectively. The difference between the two
groups is significant (p= 0.006).
Publication Bias
The Egger and Begg tests found no consistent evidence of
reporting bias (z = −0.07, p = 0.94 and z = −0.99, p = 0.32,
respectively). Likewise, the funnel plots showed little evidence of
consistent bias (Figure 3) as shown by an approximate symmetric
pattern on either side of the 95% CI boundary.
Meta-Regression
A meta-regression was performed, including four moderators of
the publication year (range= 2,003–2,020), cancer type (0= pure
or 1 = mixed), mean age (in years) of the sample (range = 24–
74) and the length of the FCR measurement (0 = single-item or
1 = multi-item) (Table 3). No statistically significant effects of
these moderators were found (all p levels > 0.4). In addition, we
investigated the potential difference between single cancer type,
such as the head and neck cancer, and the other cancers but again
no reliable effect was shown (z=−0.26, p= 0.79).
DISCUSSION
The present study is the first systematic review and meta-
analysis to investigate the gender difference of FCR specifically.
It demonstrated a significant association between gender and
FCR level, with a moderate overall effect size of 0.30 in a pooled
sample of 33,339 from 29 studies, and the two groups “pure”
and “mixed” reported consistent effect sizes of 0.28 and 0.29,
indicating females with greater FCR levels. Only two studies from
Guangzhou, China reported slightly higher FCR in males but the
differences are not statistically significant (Yang et al., 2019; Luo
et al., 2020). The overall effect size value stays stable with the
removal of any single study. The quality assessment assured a
good methodological standard for all the included studies, and
no consistent bias was found.
Previously, it seems an apparent consensus among clinicians
that a gender difference of FCR exists. However, there are many
studies demonstrating no significant association between gender
and FCR level. Some previous comprehensive systematic reviews
to investigate possible determinants of FCR involved gender in
their analysis (Crist and Grunfeld, 2013; Koch et al., 2013; Simard
et al., 2013). However, given that gender was not the focus of
their analysis, its role was not discussed in detail. The result of
the present review has clarified the potentially confused pattern
of previous results in understanding the relationship between
gender and FCR. That is, women report higher levels of FCR than
men, and this feature is one that clinicians and researchers can
factor into their practice and future studies.
Possible Reasons for FCR Gender
Differences
An explanation of the gender difference of FCR is likely to be
multifactorial. The etiology of FCR development is complex and
is poorly understood. The basis of how gender might influence
FCR can be speculated upon from various sources. In general,
gender differences are common and well-described in mental
and psychological conditions among common people as well
as cancer patients, and negative conditions are more prevalent
in women than men (Faravelli et al., 2013; Salk et al., 2017;
Aminisani et al., 2021). A recent study demonstrated that the
frequency of psychological distress is especially high among
women with colorectal cancers (Aminisani et al., 2021). Another
study reported that female sarcoma patients have lower health-
related quality of life (HRQoL) (Eichler et al., 2020). Specifically,
first, gender differences of social and psychological indicators are
associated to factors of income (Reiss, 2013), exposure to violence
(Koss et al., 1995) and the division of labor by gender (Wood and
Eagly, 2012). These social factors also apply to cancer patients,
and women cancer patients usually need more social and mental
support (Ozbayir et al., 2019). These have been explained as
largely stemming from the gender inequality against women


























TABLE 1A | Summary characteristics of the included studies in pure group.




Wagner et al. (2018) 136 54.3 (12.6) Melanoma Mean score (SD)
Female = 32.2 (±8.4)
Male = 28.5 (±8.0)
Female FoP-Q-SF Germany Cross-sectional
Koch-Gallenkamp et al.
(2016)
1,052 69 Colorectal Cancer Mean score (SD)
Female = 28.5 (9.6)
Male = 25.6 (8.2)
Female FoP-Q-SF Germany Cross-sectional
Sarkar et al. (2014) 239 50.4 (12.6) Hematological
Cancers
Multiple linear regression analysis b =
4.45
Female FoP-Q-SF Germany Prospective
clinical trial
Mirosevic et al. (2019) 216 62.3 (9.7) Head and Neck
Cancer
Age-adjusted univariate regressions
Beta = 0.337 t = 0.502 P = 0.62
NS CWS the Netherlands Cross-sectional
Humphris et al. (2003)a 87 58.3 (11.3) Orofacial Cancer Recurrence concern frequency; n (%)
Male 50 (82%)
Female 22 (85%)
NS CWS UK Prospective
(Sample 1)
Humphris et al. (2003)b 50 58.3 (11.4) Orofacial Cancer Recurrence concern frequency; n (%)
Male 22 (63%) Female 10(67%)
NS CWS UK Cross-sectional
with follow up
(Sample 2)
Borreani et al. (2020) 75 N/A Hematological
Cancer
Multiple linear regression
B = 0.416 SE = 0.153 β = 0.306 t
= 2.724
Female FCRI Italy Cross-sectional
Fisher et al. (2016) 10969 ≥65 6,772
<65 4,197
Colorectal Cancer Binary logistic regressions; Male = 1
OR (95% CI) 1.59 (1.48, 1.72)
Female Single question UK Cross-sectional
Deimling et al. (2006a)a 96 N/A Colorectal Cancer Mean (SD)
Female 10.9 (3.2) Male 11.7 (3.1)
Female 4 items USA Cross-sectional
Mullens et al. (2004) 41 56.1 Colorectal Cancer Women 2.08 (0.88)
Men 2.07 (0.64)
NS Single question USA Cross-sectional
Steele et al. (2007) 91 ≤60 years 32
61–70 years 39
>70 years 20
Colorectal Cancer Chi-square test p = 0.52 NS Single question UK Cross-sectional





Chi-square p = 0.86 NS PCI UK Clinical cohort trial
Erim et al. (2013) 70 58.1 (15.5) Malignant
Melanoma
Multiple linear regression
Z = −2.447; p = 0.014
Female FoP-Q Germany Cross-sectional
Humphris et al. (2018) 53 67 Colorectal Women 9.000 (3.406)
Men 8.563 (4.071)
Female FCR4 UK Cross-sectional
Head Neck 5000 -
NHS Foundation Trust
(2016)






Female FCR4 UK Prospective
longitudinal













































































TABLE 1B | Summary characteristics of the included studies in mixed group.




Götze et al. (2019) 1,002 66.7 (10.5) Mixed Mean (SD)
Male22.1 (8.4)
Female 27.4 (9.5)
effect size d = 0.593
Female FoP-Q-SF Germany Cross-sectional
van de Wal et al. (2016) 2,615 63.6 (12.9) Mixed Male 2.64
Female 2.84 (1.00)
t = −4.898 effect size d = 0.19
Female IOC-HWS The Netherlands Cross-sectional
Stephens et al. (2016) 6,099 <65 n = 2,595




Female CPILS USA Cross-sectional
Matthews (2003) 123 54.96 Mixed Analysis of covariance, Mean(SD)
Male = 5.64 (SD 3.44)
Female = 5.69 (SD 3.84)
F = 0.01 df = 1, 121
Female QOL-F/CS USA Cross-sectional
Baker et al. (2005) 752 18–54 years 50%
>54 years 50%
Mixed Chi-square tests
OR (95% CI) 1.5 (1.23–1.75)










Female FRQ Canada Cross-sectional
Mellon et al. (2007) 207 65 (6.2) Mixed Point biserial correlations
r = 0.04
NS FRQ USA Cross-sectional
Langeveld et al. (2004) 400 24 (4.9) Mixed Mean (SD)
Male 7.3 (2.7)
Female 8.2 (3.0) effect sizes d= 0.31
p < 0.05 t-test
Female Single item Netherlands Cross-sectional
Deimling et al. (2006a)b 321 72.3(7.5) Mixed Regression 1 = Female
Item 1–4: r = −0.07, −0.02,
−0.02, −0.02
Female Four items USA Cross-sectional
Gemmill et al. (2010) 307 74 (8.7) Mixed Mean score
Female 7.0 Male 7.9 p = 0.02
Female HRQOL USA Cross-sectional
Hinz et al. (2014) 2059 62.4 Mixed Two-way ANOVAs
d (effect size) = 0.52
Female FoP-Q-SF Germany Prospective
Mikkelsen et al. (2009) 340 59.5 (11.5) Mixed Positive answers number, N (%)
Male 51 (40.8) Female 125 (58.1)
NS Single question Denmark Cross-sectional
Luo et al. (2020) 996 48.04 (11.71) Mixed Multivariable logistic regression
Female Exp (B) = 1.292 P = 0.348
Male (NS) FoP-Q-SF China Cross-sectional
Yang et al. (2019) 1025 <35 years 14.2%
35–60 years 65.9%
>60 years 19.9%
Mixed t (df) = 1.13 (1,023) Male (NS) FCR7 China Cross-sectional
Abbreviations of FCR measurements: FoP-Q, Fear of Progression Questionnaire; FoP-Q-SF, Fear of Progression Questionnaire-Short Form; CWS, Cancer Worry Scale; FCRI, Fear of Cancer Recurrence Inventory; PCI, 45-item Patient
Concerns Inventory; FCR4 or FCR7, 4 or 7 item version of the Fears of Cancer Recurrence Scale; IOC-HWS, The Health Worries subscale of the Impact of Cancer scale; CPILS, Cancer Problems in Living Scale; QOL-F/CS, Quality of
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TABLE 2A | Quality assessment by modified Joanna Briggs tool on the included studies in pure group.




Item 3 confounds Item 4 strategies Item 5
measure-ments
Item 6 statistics Overall score (6
max)
Pure group
Humphris et al. (2003)a 5
Humphris et al. (2003)b 5
Mullens et al. (2004) 5
Deimling et al. (2006b)b 6
Steele et al. (2007) 3
Erim et al. (2013) 5




Fisher et al. (2016) 4
Wagner et al. (2018) 6
Humphris et al. (2018) 4
Mirosevic et al. (2019) 6
Borreani et al. (2020) 6
Rogers et al. (2010) 4




Green = “Yes”; Red = “No”; Yellow = “Unclear/Not applicable.” The a,b mean to differentiate them as described in Results-Study Selection.
TABLE 2B | Quality assessment by modified Joanna Briggs tool on the included studies in mixed group.




Item 3 confounds Item 4 strategies Item 5
measure-ments




Langeveld et al. (2004) 5
Baker et al. (2005) 5
Deimling et al. (2006b)a 6




Mikkelsen et al. (2009) 5
Gemmill et al. (2010) 4
Hinz et al. (2014) 4
van de Wal et al. (2016) 6
Stephens et al. (2016) 6
Götze et al. (2019) 6
Luo et al. (2020) 6
Yang et al. (2019) 6
Green = “Yes”; Red = “No”; Yellow = “Unclear/Not applicable.”
within society but vary widely on a cross-nation level (Salk
et al., 2017). Second, women cancer patients are more inclined to
express their problems and seek for help, while men patients may
abstain from expressing fear or worry when suffering a negative
condition because of feelings of shame (Clover et al., 2015; Anuk
et al., 2019). This implies that women may tend to report higher
FCR level.
The Comparison Between Groups and the
Heterogeneity
Many studies with mixed cancer types included gender-specific
cancers when assessing the effect of gender. This may have
potential impact on the gender distribution of study samples and
gender-related analysis, and lead to bias of study results. Given
this concern, we divided all the included studies into “pure” and
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FIGURE 2 | Forest plot of fears of cancer recurrence (FCR) and gender in a random-effects model. Weights are from random-effects model.
“mixed” groups. The cancer type seems to have a very limited
effect, and less than expected on effect sizes of the two groups,
resulting in almost identical values (0.28 vs. 0.29). However,
the heterogeneity of the mixed group is much greater than the
pure group, leading the overall heterogeneity to a similarly high
level. This was to be expected because studies of the mixed
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FIGURE 3 | Funnel plot of the four covariates: year of publication, cancer type, age of sample, and FCR measurement on gender by fears of cancer recurrence (FCR)
association effect sizes (z).
group have more diverse samples with various types of cancer
including gender-specific cancers and in addition the authors
adopted more complex data analytical approaches. They also
used, on inspection, a more variable set of FCR measurement
tools. Most of the studies of the pure group used standardized
questionnaires such as the Fear of Progression Questionnaire
(FoP-Q) or the 4 item version of the Fears of Cancer Recurrence
Scale (FCR4), while in the mixed group, almost all the studies
used study specific FCR measures ranging from a self-defined
single question, 4-item scale, to subscales extracted from various
other questionnaires such as the Cancer Problems in Living Scale
(CPILS), the Health Worries subscale of the Impact of Cancer
scale (IOC-HWS) or Health-related Quality of Life (HRQOL).
The exception to this rule were three studies that consistently
used the FoP-Q short form (Hinz et al., 2014; Götze et al., 2019;
Luo et al., 2020). This possible complication, may reflect itself in
the observed level of heterogeneity of the mixed group as well
as the overall statistics. We consider this may not influence our
conclusion substantially because the heterogeneity of the pure
group stays at a very low level, and the pure group possessed an
TABLE 3 | Meta-regression of effect sizes by four covariates: year of publication,
cancer type, age of sample, and FCR measurement on gender by fears of cancer
recurrence (FCR).
Moderators B coef SE t P 95% conf. interval
Year of publication 0.000 0.008 0.02 0.983 −0.016 0.017
Cancer type 0.005 0.088 0.05 0.957 −0.176 0.185
Age of sample 0.003 0.004 0.75 0.459 −0.006 0.012
FCR Item length 0.047 0.105 0.45 0.660 −0.170 0.264
almost identical effect size as the mixed group and subsequently
the overall result.
Moderator Variables
We performed a meta-regression including four moderator
variables of: cancer type, publication year, mean age of the
sample and single- or multi-item FCR measurement, because
these factors have potential effects on FCR level. FCR level
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differs among patients with different cancer types (Crist and
Grunfeld, 2013; Simard et al., 2013), which was also discussed
in the gender-specific cancer relevant section in this review.
In a meta-analysis about the relationship between age and
FCR, the authors found the more recent the study, the
strength of the effect size decreases (Lim and Humphris, 2020).
Several studies demonstrated a relationship between patient
age and FCR. The older the cancer patients, the lower the
reported FCR level (Simard et al., 2013; Lim and Humphris,
2020). Furthermore, given that there is no consensus on the
measurement tool of FCR, the methods in literatures vary
from the 43-item Fear of Progression Questionnaire (FoP-Q)
(Erim et al., 2013) to a single-item question like “I have fear
about my cancer coming back” (Fisher et al., 2016), which
generate different FCR results. However, no significant result
of the moderator variables was found in the present study,
demonstrating they might have less effect than expectation. But
in consideration of the previous positive evidence mentioned
above, these factors are still important in future studies to be
explored further.
Clinical Implications
In clinical communication, clinicians play a crucial role and often
occupy an important position from the patient’s perspective. It
has been recommended that clinicians should pay attention to
the discussion of FCR with cancer patients. There are studies
showing that non-mental health trained clinicians can provide
effective interventions for FCR (Liu et al., 2019). But this is
still challenging because non-mental health trained oncologists
often have difficulties in deciding which patients need such
assistance. There are tools developed to assist clinicians to
be aware of cancer patients’ individual needs, such as the
Patient Concerns Inventory (PCI), a checklist where patients
can select the items they want to discuss at a clinic, including
the fear of cancer recurrence (Rogers et al., 2018). However,
it may be of benefit if the more easily obtained demographic
characteristics, such as gender and age, can be used as easily
available indicators to help clinicians to focus on the discussion
of FCR with patients at high risk. The result of this review
fits our prediction and supports clinicians who consider gender
as a useful indicator of FCR level. It might help clinicians
to focus discussion of FCR with patients attending follow-up
clinics when combine their gender with other easily obtained
demographic characteristics, and help improve the efficiency of
doctor-patient communication.
Strengths and Limitations
This review has a number of strengths including the systematic
search for all quality studies that reported the relationship
between fears of recurrence or progression with gender.
In addition, this is the first study to utilize meta-analytical
and meta-regression methodology to assist interpretation
of a substantial pooled sample of reported investigations.
However, this systematic review and meta-analysis has
several limitations. First, to completely avoid the potential
bias from gender-specific cancers, only papers about both-
gender cancers should be included. However, only sixteen
studies have met this criterion, which provides some
evidence but not extensive. Therefore, we included gender-
specific cancers and divided these studies into two groups
(“pure” and “mixed”) as outlined already with the additional
analysis to study the effect of cancer types, that showed no
statistical significance. Second, this review excluded papers
not written in English, which may reduce its generalisabilty to
some extent.
Future Directions
In the literatures on FCR so far, gender has been usually regarded
as a “not-so-important” factor out of various demographic
characteristics. The effect of gender should be investigated
with greater consideration and authors in the FCR field are
encouraged to report FCR levels by gender. When attempting
to assess the factor of gender, cancer types that only a
single gender can contract should be considered carefully in
their interpretation when intending to investigate gender FCR
differences. An argument can be voiced to exclude such cancer
types in assessing gender and FCR association to avoid possible
confusion. In terms of the high-level heterogeneity observed
in the mixed group of this review, while the mixed group
of studies may have included a wider selection of patient
samples the varied measurements employed indicated that
an international consensus on the FCR measurement may
be helpful to reduce the number of measures and possibly
strengthen consistency. In addition, authors of future studies
are commended to include in their manuscript results a
breakdown or association statistic of gender and FCR to assist
any review update and strengthen our understanding of this
key relationship.
CONCLUSION
In this systematic review of studies over the past 20 years,
the previous confusing pattern of outcomes reported in the
literature of the relationship between gender and FCR was
clarified. Women report higher levels of FCR than men, a finding
that clinicians and researchers can factor into their practice and
future research with care to avoid possible stereo-typing. With
only a moderate effect size, indicating that the level of FCR was
somewhat variable, independent of gender, demonstrates that
further study is required.
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